Cingulate Inc. (CING)
- Previous Close
3.9800 - Open
3.9800 - Bid 3.8100 x 100
- Ask 3.9400 x 100
- Day's Range
3.8300 - 4.3473 - 52 Week Range
1.8000 - 20.8300 - Volume
169,835 - Avg. Volume
95,455 - Market Cap (intraday)
14.734M - Beta (5Y Monthly) -0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-10.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.40
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
www.cingulate.comRecent News: CING
View More
Performance Overview: CING
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CING
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CING
View MoreValuation Measures
Market Cap
14.73M
Enterprise Value
7.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-106.54%
Return on Equity (ttm)
-5,305.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.55M
Diluted EPS (ttm)
-10.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.21M
Total Debt/Equity (mrq)
68.39%
Levered Free Cash Flow (ttm)
-12.84M